spacer
home > epc > spring 2017 > transforming software
PUBLICATIONS
European Pharmaceutical Contractor

Transforming Software

With the wide-scale adoption of clinical technologies, focus has slowly shifted from ‘how can we leverage new software and systems in our clinical trials?’ to ‘how can we best implement this software once we’ve chosen it?’ In a highly regulated industry, with patient safety and new treatment advances at stake, the priority has historically been compliance and risk management. Now that these systems are mature and reliable, identifying new ways to make them available in a more efficient and timely manner is important. Utilising iterative design is one way to address these needs.

The Triple Constraint

Anyone who has developed software or managed projects is familiar with the triangle concept – any movement of one factor impacts the equilibrium. For example, increasing the complexity of a clinical supply tool is sure to extend time to implement and development costs. Using an iterative approach helps manage these constraints as well as scope, and maintain quality while reducing time and cost.

Innovation to Date


Quality is of paramount importance with a clinical interactive response technology (IRT) system. When patients are being treated and new drugs developed, quality cannot be compromised. This quality profile must be maintained amid increasingly complex protocol designs, shorter timeline requirements and tighter budgets.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Steve Rawbone
spacer
spacer
spacer
Stephane Delegar
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BBI Solutions broadens antibody portfolio and strengthens reagent technical support capabilities with acquisition of Maine Biotechnology Services

BBI, a leading manufacturer of raw materials and finished test platforms, already provides human antigens, antibodies, serum and plasma products and clinical chemistry enzymes, for the in-vitro diagnostics market. Now with the acquisition of MBS they have strengthened their antibody offering, providing a comprehensive portfolio and custom services to deliver a total reagent solution for any immunoassay development.
More info >>

White Papers

ConsulTech GmbH

ConsulTech GmbH

ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
More info >>

 
Industry Events

Drug Discovery 2018

21-22 March 2018, Copthorne Tara Hotel, Scarsdale Place, Kensington, London

SMi Group is proud to announce the return of Drug Discovery in 2018. The successful conference will return for its 2nd year on the 21st and 22nd March.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement